NDRAENDRA Life Sciences Inc.
Health Care
Proceeds from Issuance of Common Stock revised up 367.4% for FY 2024
This is the 2nd largest revision in NDRA's history.
Proceeds from Issuance of Common Stock·FY 2024
Major restatement$5.4M▲ 367.4%
was$1.1M
Revised up in a S-4.
No amendment filed
As reported · Mar 31, 2025S-4 · Oct 2, 2026us-gaap:ProceedsFromIssuanceOfCommonStockVerify against SEC filingsShow
As reported$1.1M
Accepted 2025-03-310001654954-25-003612
Restated$5.4M
Accepted 2026-10-020001193125-26-410883
CommonStockIssuance · reported 4 times · point-in-time, survivorship-free. Every figure traces to its filing above.
Track this the moment it happens
Get a signal the next time NDRA — or any company on your watchlist — restates a number. Every signal lands with the diff and its source filing.